Creative Solutions to Launching & Funding

Early Stage Bioscience Companies in the New Economy

Creative Solutions to Launching & Funding

Early Stage Bioscience Companies in the New Economy

April 16, 2009 7:30-10:30 AM

University of MarylandBioPark Building Two

801 W. Baltimore Street, Baltimore, MD 21201

Halima Aquino, MA Principal, Bolton Hill Consulting, Ltd.

Halima Aquino, MA Principal, Bolton Hill Consulting, Ltd.

Founded Bolton Hill Consulting, Ltd, 2008 to develop innovative communication strategies for science based entrepreneurs in aerospace, bioscience & healthcare:

Provides strategic community outreach & collaborative partnership planning in the industry, education & government environments.

Provides strategic communications through social networking, event planning, speaking engagement planning & focus groups.

Founded & Launched LilyPad Sensors Corporation in 2006.

Former Director of Internal Services & Commuications, Martek Biosciences

Former Industry Strategy Manager, Maryland Governor’s Workforce Investment Board & Baltimore Mayor’s Workforce Investment Board

Master’s Level Psychologist with clinical research, program management, interviewing, group facilitation, & psychological testing skills.

Academics: ACTiVATE Technology Entrepreneurship Training, UMBC, M.A. Clinical Psychology (All but Dissertation), University of Maryland & B.A., International Relations & French, College of Wooster.

Member & Volunteer: Emerging Companies Roundtable, GBTC, MDBioProgram Planning Committee, MIT Enterprise Forum of DC, Maryland Women in Technology & the Global Women’s Technology Collaborative

James N Campbell, MD President & CEO, Arcion Therapeutics Inc. & Executive in Residence, InterWest Partners

James N Campbell, MD President & CEO, Arcion Therapeutics Inc. & Executive in Residence, InterWest Partners

Director of InterWest portfolio companies Anesiva & Amplimmune

Founder, President & CEO of Arcion Therapeutics Inc. a venture-backed company focused on the development of targeted therapies for chronic pain.

Founder & Chairman Emeritus, American Pain Foundation.

Professor of Neurosurgery & Director of the Blaustein Pain Treatment Center School of Medicine , JHU

Authored several books, & 100 peer-reviewed research papers.

National awards for research & public service, including: Jacob Javits Neuroscience Investigator Award, NIH Grass Award, Society of Neurological Surgery Kerr Award for Research, American Pain Society

M.D.,Yale Univ., Residency in Neurosurgery, JHU & Post-doctoral training in Neurophysiology, JHU. B.A., Univ. of Michigan

Diplomate, American Board of Neurological Surgery

Paul Silber, Ph.D.Principal, Silber & Associates &

Director, Evergreen Capital

Paul Silber, Ph.D.Principal, Silber & Associates &

Director, Evergreen Capital Former President/CEO & Founder, In Vitro

Technologies, Inc. (IVT), a bioscience company that provided products & services to pharmaceutical & biotechnology companies.

Grew company to 60 employees & $11M in revenues without venture capital

Successfully sold the company to Celsis plc in 2006 for $30M.

Received these business awards among others: MD Entrepreneur of the Year Award (High Technology) GBTC Beta Award Washington Techway’s top 10 Bosses GBC Leadership in Bioscience Award State of Maryland’s International Leadership Award

Board Membership: Chair, GBTC Biotech Roundtable, Biotechnical Institute of Maryland, TechCenter at UMBC Business Advisor & Dean’s Advisory, UMBC College of Natural Sciences.

Ph.D. in Pharmacology & Toxicology, Univ. Arizona, Master's degree in Public Health, Univ. Alabama & B.S. in Biology, Carleton College

Dan K. Morhaim, M.D.

Member, Maryland House of Delegates Dan K. Morhaim, M.D.

Member, Maryland House of Delegates Only physician in the Maryland House of Delegates

Focuses on health care, the environment, & streamlining government operations

Deputy Majority Leader, serves on the Health & Government Operations Committee

Chairs the sub-committee on Government Operations. House Chair of the Joint Committee on Health Care Delivery &

Finance. Chair, Legislative Biotech Caucus (founded 1st biotechnology

caucus)

Board-Certified, Internal Medicine & Emergency Medicine.

Founding Chair, Emergency Medicine, Franklin Square Hospital

On staff at Sinai, Northwest, & the Health Care for the Homeless & on faculty, JHH School of Public Health

Serves on the Board of UMBI

James A. Poulos, III, J.D.VP of Technology Transfer & Commercialization

Maryland TEDCO

James A. Poulos, III, J.D.VP of Technology Transfer & Commercialization

Maryland TEDCO At TEDCO:

Oversees tech transfer funding program, including Maryland Technology Transfer Fund

Is creating an angel network for TEDCO Portfolio companies.

Former Executive & Acting Director, Office of Tech Commercialization, UMCP 1998-2000

Managed US patent portfolio at Zambon Group S.p.A. (Zambon).

Since 1980: written over 150 patent applications & prosecuted at > 1,000 applications. 

Former adjunct faculty member of UB’s Merrick School Of Business.

 B.S Chemistry, UMCP, 1979, J.D, UB, 1984  

Membership in ABA, AIPLA, MPLA, AUTM, LES                        

Lawrence Mahan, PhDActing Executive Director

Maryland Biotechnology Center

Lawrence Mahan, PhDActing Executive Director

Maryland Biotechnology Center

As acting Executive Director for MBC, showcases & supports biotechnology innovation & entrepreneurship in Maryland.

Joined DBED in 2001 as Senior Strategic Advisor for Biosciences to DBED & the Governor

Oversees programs of business development, strategic partnering, & industry initiatives in one of the largest clusters of bioscience companies & federal research laboratories in the United States.

10 years in the U.S. DHHS as Senior Scientist

Author of over 100 published articles & abstracts

Holds 4 US patents: biology, functional genomics, neuroscience, pharmacology, immunology & biochemistry.

Ph.D., University of California, San Diego, California & Post Doctoral Training, (NIH).

Youseph Yazdi, PhD, MBACorporate Director

Corporate Office of Science & TechnologyJohnson & Johnson

Youseph Yazdi, PhD, MBACorporate Director

Corporate Office of Science & TechnologyJohnson & Johnson

At COSAT responsible for building Johnson & Johnson's open innovation network to nurture health care innovation.

Member of several task forces, including: Energy-Based Therapeutics, RFID, Urology & Sexual Health, Neuroregeneration/Neuromodulation, Medical Optics, & MEMS & Nanotechnology.

Ph.D., Biomedical Engineering, In Optical Spectroscopy, University of Texas at Austin., MS, in the detection of malignancy associated changes in breast & cervical cells, UTA, BS in Electrical & Computer Engineering, Rice University, & MBA, Wharton School

Fellow, American Institute for Medical & Biological Engineering

Advisory Board Member: University of Michigan, the University of Virginia, Drexel University, Georgia Tech, Boston University, & the Wallace H. Coulter Foundation

Investment Advisory Board Member: Virginia Center for Innovative Technology & Maryland Technology Development Corporation

Margaret Anderson, M.A. Chief Operating Officer, FasterCures

Margaret Anderson, M.A. Chief Operating Officer, FasterCures

Former Deputy Director & Team Leader for the Center on AIDS & Community Health Educational Development (AED) in Washington, D.C

Former Program Director for the Society for Women’s Health Research.

Former Health Science Analyst at the American Public

Health Association working on a portfolio of public health issues.

Former analyst & project director at the Congressional Office of Technology Assessment working on studies requested by Congressional committees related to the use of genetic testing in a variety of settings.

Serves as a member of the Whitman Walker Clinic Institutional Review Board in Washington, DC.

MA in Science, technology & public policy from GWU Elliott School of International Affairs

Matt Zuga, M.B.A. Founder & Managing Director

Red Abbey Venture Partners

Matt Zuga, M.B.A. Founder & Managing Director

Red Abbey Venture Partners

Responsible for managing all of Red Abbey’s investments, Including 24 companies: 15 privately held & 9 publicly traded.

Current member of the Board of Directors of Arginetix, Inc.

Current BOD observer at Advanced BioHealing & Alba Therapeutics Corporation & Former BOD observer, Sirtris Pharmaceuticals (prior to IPO).

Former Managing Director in the investment banking department of Legg Mason Wood Walker, Inc. & Head of the Life Sciences Group.

Prior work experience includes: Raymond James & Associates, Inc. (investment banking), Southeast Bank, N.A. (commercial lending), IBM Corporation (finance

department) & GMC Corporation (industrial engineering).

MBA, Kenan-Flagler Business School, UNC at Chapel Hill, 1993 & BS, OSU, 1988

Elizabeth Good, M.S.Director, Strategic Investments

University of Maryland, Baltimore

Elizabeth Good, M.S.Director, Strategic Investments

University of Maryland, Baltimore Former Managing Director, Maryland Venture Fund

Managed a portfolio of 85 life science & IT companies, plus 9 venture capital LP investments (>$40 million in investment)

Represented the State as advisor &/or BOD observer at 15+ bioscience portfolio companies, including A&G Pharmaceuticals, Advanced BioNutrition, Chesapeake PERL, Cylex, Cytimmune Sciences, Innovative Biosensors, etc.

Former product development engineer for 2 venture-backed point-of-care cardiovascular diagnostic companies:

Accumetrics provides industry-leading diagnostic tests for platelet function assessment.

Automedics was acquired by Gensia Pharmaceuticals.

Committee Work includes: DBED Transition Team Sub-Committees on Venture Capital, Maryland Life Sciences Advisory Board & SBIR review panels

M.S. in Bioengineering, UCSD & B.S. in Biomedical & Electrical Engineering, Duke University

Ravinder Dhallan, M.D./Ph.D. M.B.A.Founder, Chairman & CEO, Ravgen

Ravinder Dhallan, M.D./Ph.D. M.B.A.Founder, Chairman & CEO, Ravgen

Founded Ravgen in September of 2000 & Invented Ravgen's proprietary technology. Provided leadership for Ravgen's business strategy

Extensive & diverse training in biomedical engineering, clinical research, & medicine

Published numerous articles on genetic research in widely recognized & internationally accepted peer-reviewed journals.

A residency-trained, board-certified emergency room physician.

M.D. & Ph.D. (Biomedical Engineering), JHU School of Medicine & MBA from The Wharton School of Business, UPenn.

Kris Appel, M.A.

President & CEO, Encore Path, Inc. Kris Appel, M.A.

President & CEO, Encore Path, Inc.

VP of US Operations for e4e, a global technology services company managing over 500 employees in 3 locations

Spent 17 years at the NSA roles included:Internal Communications Director for the Director of NSA & Senior Director of Operations Policy

MA in Romance Linguistics, University of Michigan, 2006 graduate of the ACTiVATE technology entrepreneurship program at UMBC.

1st place winner of two business plan competitions

Founder of the Apple Harvest Giving Circle, raising

funds for educational & health-related charities.

Ginette Serrero, Ph.D.Co-Founder & CEO

A&G Pharmaceuticals

Ginette Serrero, Ph.D.Co-Founder & CEO

A&G Pharmaceuticals

Internationally recognized scientist for her work on adipocyte differentiation & breast cancer.

> 80 published papers & inventor on 8 issued patents (US & International) & 14 recently filed patents.

Current Adjunct Professor of Pharmaceutical Sciences & Pathology, UM Cancer Center & Former Full Professor, Pharma Sciences, Oncology, UM School of Pharmacy & Greenebaum Cancer Center.

In Academia, Dr. Serrero received: > $ 5 million grant awards : including NIH, DOD, Juvenile Diabetes Foundation, AHA, & the Susan G. Komen Breast Cancer Foundation

PhD, Biochemistry, D. Sc, Cell Biology, University of Marseille & Nice in France & Post-doctoral fellow, UCSD with Dr. Gordon Sato